SecBot SecBot
Biotech Drug Report Generated Jul 3, 2026

Proleukin

IOVA·IOVANCE BIOTHERAPEUTICS, INC.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 1992 (FDA)
Why 3/10
Proleukin is an already-approved, marketed drug with no pending regulatory decision or pivotal readout specific to it. There is no hard dated binary catalyst for this drug in the next ~12 months. The next major catalysts for IOVA stock relate to Amtagvi (lifileucel), the TIL-301 Phase 3 confirmatory trial readout and potential NSCLC label expansion, not to Proleukin. At ~17% of Iovance's product revenue, Proleukin is a modest, steady revenue contributor but not a share-price swing factor.
Actionable Insight NEUTRAL

Proleukin is a steady, low-growth commercial asset for Iovance, providing ~$44M-60M in annual revenue (17% of total product sales). It functions largely as a support drug for Iovance's flagship TIL therapy Amtagvi. For IOVA investors, the stock's binary catalysts revolve around Amtagvi's label expansion (Phase 3 frontline melanoma, NSCLC), not Proleukin. Proleukin's main risk is gradual revenue erosion from newer engineered IL-2 competitors and potential biosimilar entry given its long-expired patents.

Price Chart

Loading chart...

Executive Summary

Proleukin (aldesleukin) is an older, FDA-approved recombinant IL-2 immunotherapy for metastatic renal cell carcinoma and metastatic melanoma, first approved in 1992. Iovance Biotherapeutics (IOVA) acquired worldwide rights from Clinigen in January 2023 for £166.7M upfront. The drug generated ~$60.5M in revenue for Iovance in FY2024 and ~$44M in FY2025 (~17% of total product revenue). Proleukin is strategically important to Iovance because it's used in the conditioning regimen for its flagship TIL therapy Amtagvi (lifileucel). However, as an already-approved drug with no pending FDA decision or pivotal readout, Proleukin itself is not a binary catalyst stock driver. The IOVA thesis centers on Amtagvi's commercial ramp and label expansion, while Proleukin provides steady, modest supplemental revenue.

How It Works

Proleukin is a synthetic version of interleukin-2 (IL-2), a protein the body's immune system naturally produces. It works by stimulating the growth and activity of T cells and natural killer (NK) cells, key types of immune cells that attack cancer. It is given intravenously and essentially 'kick-starts' the immune system to fight tumors. However, it is known for severe side effects, most notably capillary leak syndrome (fluid leaking from blood vessels into tissues), which requires treatment in a hospital setting with careful monitoring.

Trial Status

FDA-approved since 1992 for metastatic renal cell carcinoma and metastatic melanoma. Iovance acquired worldwide rights in January 2023 and currently markets the drug commercially. Proleukin is used in the conditioning regimen for Iovance's Amtagvi (lifileucel) TIL therapy and also sold for other commercial/clinical uses. Orphan Drug Designation was granted for ALS in 2021 (by prior owner Clinigen), but Iovance has not disclosed active late-stage development in that indication.

The Two-Sided Case

▲ Bull Case5
Proleukin provides a steady, predictable revenue stream (~$44-60M/year) with established commercial infrastructure, contributing to Iovance's top line with no additional R&D investment required.
Proleukin is integral to the Amtagvi TIL therapy regimen, creating a bundled commercial strategy where growth in Amtagvi prescriptions also drives Proleukin demand.
The acquisition (fully paid in Jan 2023) also secured IL-2 supply for Iovance's clinical and future commercial TIL manufacturing, vertically integrating a key input.
Iovance is developing a next-gen modified IL-2 analog (IOV-3001) that could eventually provide an upgraded successor, potentially extending the franchise.
The global IL-2/aldesleukin market is projected to grow at a ~6.8% CAGR, reaching ~$394M by 2034, providing a tailwind for steady Proleukin sales.
▼ Bear Case5
Proleukin is a mature, off-patent drug (composition patents expired early 2010s) facing eventual biosimilar competition that could erode pricing and revenue.
Newer engineered IL-2 therapies (PEGylated, masked, non-alpha-binding variants) from competitors aim for better tolerability and efficacy, potentially displacing native IL-2 over time.
Proleukin represents only ~17% of Iovance's product revenue, Amtagvi is the real value driver. IOVA stock moves on Amtagvi data and sales, not Proleukin's modest contribution.
The drug carries a black-box FDA warning for capillary leak syndrome, serious neurologic toxicity, and infections, limiting its addressable patient population to those with normal cardiac/pulmonary function.
Iovance's Q1 2025 revenue miss ($49.3M vs $83.27M expected) and subsequent 19% workforce reduction in August 2025 highlights execution risk that could impact both Amtagvi and Proleukin commercialization.

Upcoming Catalysts

  • Amtagvi (lifileucel) Phase 3 TILVANCE-301 confirmatory trial readout in frontline advanced melanoma (key IOVA catalyst, not Proleukin-specific)
  • Potential FDA decision on Amtagvi label expansion into second-line non-small cell lung cancer (Fast Track granted)
  • Iovance Q2 2026 earnings (early August 2026), Proleukin revenue trends as part of total product revenue
  • Quarterly sales trajectory showing Proleukin's steady-state run rate as Amtagvi adoption grows

Source Filing

The SecBot filing or press-release report that triggered this drug report:

IOVANCE BIOTHERAPEUTICS, INC. 8-K IOVA ·Originating report

Sources · 12

Hover a chip for the title
1 clinigengroup.com2 dlapiper.com3 einpresswire.com4 ibtimes.com.au5 accessdata.fda.gov6 stocktitan.net7 dataintelo.com8 openicon.com9 pharmavanguard.com10 nasdaq.com11 sec.gov12 iovance.com